Transcript Multiple Myeloma: Transplant Setting

What Clinicians Want to Know
A Live CME Event Addressing the Most Common
Questions and Controversies in the Current Clinical
Management of Select Hematologic Cancers
Sunday, June 5, 2011
7:00 PM – 9:30 PM
Chicago, Illinois
Moderator
Neil Love, MD
Faculty
Sergio Giralt, MD
John P Leonard, MD
Lauren C Pinter-Brown, MD
Antonio Palumbo, MD
Susan M O’Brien, MD
Professor Michael Hallek
Copyright © 2011 Research To Practice. All rights reserved.
Agenda
Module 1 – Dr Giralt: Multiple Myeloma (MM) in the Transplant Setting
Module 2 – Dr Leonard: Follicular Lymphoma (FL), Transformation and
Diffuse Large B-Cell Lymphoma (DLBCL)
Module 3 – Dr Pinter-Brown: Peripheral and Cutaneous
T-Cell Lymphomas (PTCL and CTCL) and Mantle-Cell
Lymphoma (MCL)
Module 4 – Dr Palumbo: Multiple Myeloma in the Nontransplant Setting
Module 5 – Dr O’Brien: Chronic Myeloid Leukemia (CML)
Module 6 – Prof Hallek: Chronic Lymphocytic Leukemia (CLL)
Copyright © 2011 Research To Practice. All rights reserved.
Survey of Oncologists
• General survey assessing interest level in clinical
topics related to the treatment of hematologic
neoplasms (April 15-28, 2011)
• 100 community-based medical oncologists who treat
hematologic oncology in the US
Percent of practice that is
solid tumors (median)
Percent that is hematologic
oncology (median)
69%
31%
Copyright © 2011 Research To Practice. All rights reserved.
Survey of Oncologists
• Median number of new patients seen per year with…
Multiple myeloma
Follicular lymphoma
15
20
Diffuse large B-cell lymphoma
15
T-cell lymphoma
4
Mantle-cell lymphoma
5
Chronic myeloid leukemia
6
Chronic lymphocytic leukemia
20
Copyright © 2011 Research To Practice. All rights reserved.
Survey of Oncologists
If you were to attend a CME conference on
hematologic oncology, to what extent would
you be interested in learning about the
following topics?
• Response scale 0 – 10
0 = no interest
10 = very interested
Copyright © 2011 Research To Practice. All rights reserved.
Multiple Myeloma: Cytogenetics and FISH in
Clinical Decision-Making
30%
10
53%
23%
9
16%
8
11%
7
4%
6
8%
5
4%
4
2%
3
10 = very interested
2%
2
1
0%
0
0%
0%
0 = no interest
5%
10%
15%
20%
25%
30%
35%
Copyright © 2011 Research To Practice. All rights reserved.
Multiple Myeloma: Method of Transplant
(Auto, Allo, Tandem)
10
9
8
7
6
5%
12%
7%
9%
13%
10%
18%
5
11%
10%
8%
4
3
2
10 = very interested
0 = no interest
5%
4%
1
0
0%
5%
10%
15%
20%
25%
30%
35%
Copyright © 2011 Research To Practice. All rights reserved.
Survey of Oncologists
What question(s) would you like to pose to a
clinical investigator with expertise in the
management of hematologic oncology?
• 1322 questions/cases received
Copyright © 2011 Research To Practice. All rights reserved.
Interest in Topics Related to the Treatment
of Patients with MM Who Are Transplant Eligible
(Percent Responding 9 or 10)
Cytogenetics and FISH
53%
Initial therapy for patients <65 yo
48%
New agents/regimens
46%
Post-transplant maintenance
42%
Delayed/deferred transplant
41%
Renal dysfunction in MM
34%
Management of side effects
34%
0%
10% 20% 30% 40% 50% 60%
Copyright © 2011 Research To Practice. All rights reserved.
Multiple Myeloma: Transplant Setting
• Is there a best pre-transplant induction regimen?
• Under what clinical circumstances is a triple drug
regimen preferred over a double drug regimen for
induction?
• Does SCT still play a role in up-front therapy, or
can it be reserved for patients with relapsed
multiple myeloma for whom many treatment
options have failed?
Copyright © 2011 Research To Practice. All rights reserved.
Multiple Myeloma: Transplant Setting
• Role of ASCT: Single versus tandem transplant
• 54 yo woman with great performance status
(ECOG = 0) and poor-risk cytogenetics who has
experienced a VGPR after RVD followed by
autoPBSCT. What is the best consolidation therapy —
a second autoPBSCT, a mini-alloPBSCT (+ identified
matched sibling) or maintenance treatment?
• Role of maintenance therapy in multiple myeloma
Copyright © 2011 Research To Practice. All rights reserved.